Targeted sequencing has many applications in cancer biomarker research, carrier screening and inherited disorders, drug development, mitochondrial DNA variant detection, human ID and paternity testing and the detection of rare variants in human samples.
With the introduction of our QIAseq NGS Panels in 2016, we set a new standard for targeted amplicon-based genotyping via NGS. New features such as error-correcting molecular barcodes known as Unique Molecular Indices (UMIs) and Single Primer Extension (SPE) allowed the detection of rare variants with high confidence, all from a single tube. Our panels enabled the enrichment of up to 20,000 targets while ensuring high uniformity and complete coverage.
We have now further enhanced QIAseq chemistry to improve your NGS workflow even more. New QIAseq Targeted DNA Pro panels leverage major innovations that provide you with the next level of performance. The panels ensure superior ease of use and increased workflow efficiency while facilitating high-fidelity variant analysis.
This webinar explores how the new QIAseq Targeted DNA Pro workflow fast-tracks and streamlines library preparation so that you can accelerate your time-to-result and get deeper insights faster.
1. Explain NGS applications and challenges in biomarker research.
2. Compare overview and benefits of QIAseq Targeted DNA Pro Panels.
3. Review performance data.